Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

The enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm 3mg ...

In the first clinical trial of its kind, a weekly dose of semaglutide, also known as Ozempic and Wegovy, was found to cut the amount that people drink in one day by about 40% and dramatically ...

They were then randomly assigned to receive weekly, low-dose injections of semaglutide or a placebo for nine weeks, during which time their weekly drinking patterns were also measured. Their ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...